Poland's Selvita expands US operations with West Coast office

14 March 2016

Poland-based biotech firm Selvita, the largest drug discovery company in Central and Eastern Europe, has just opened its West Coast US office, located in San Bruno, California.

Selvita initiated its US operations in September 2015, opening a fully-owned US subsidiary, Selvita Inc, headquartered in Cambridge, Massachusetts. Now the company is officially opening its second office, which is dedicated to the support of the ongoing and future projects for business partners from the West Coast of USA. Last year it also launched a subsidiary in the UK (The Pharma Letter May 5, 2015).

“The US drug discovery market is absolutely strategic for Selvita. It is not only where most of our revenue comes from, but also where we put most of our hopes in,” said Pawel Przewiezlikowski, chief executive of Selvita, adding: “We are continuously investing in top class-facilities and best professionals. In 2016 we are opening our second research facility in Poznan, Poland, and we believe we have even more to offer to our customers.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK